Cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus-associated	tacrolimus-associated	O	O	O	O
thrombotic	thrombotic	O	DISEASE	OTHERS	I
microangiopathy	microangiopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
thrombotic	thrombotic	O	DISEASE	OTHERS	I
microangiopathy	microangiopathy	O	DISEASE	OTHERS	I
(	(	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
)	)	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
well	well	O	O	O	O
documented	documented	O	O	O	O
.	.	O	O	O	O

Treatments	treatments	O	O	O	O
have	have	O	O	O	O
included	included	O	O	O	O
discontinuation	discontinuation	O	O	O	O
or	or	O	O	O	O
reduction	reduction	O	O	O	O
of	of	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
without	without	O	O	O	O
concurrent	concurrent	O	O	O	O
plasma	plasma	O	O	O	O
exchange	exchange	O	O	O	O
,	,	O	O	O	O
plasma	plasma	O	O	O	O
infusion	infusion	O	O	O	O
,	,	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
intravenous	intravenous	O	O	O	O
immunoglobulin	immunoglobulin	CHEMICALS	O	OTHERS	I
G	g	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
for	for	O	O	O	O
recipients	recipients	O	O	O	O
of	of	O	O	O	O
organ	organ	O	O	O	O
transplantation	transplantation	O	O	O	O
,	,	O	O	O	O
removing	removing	O	O	O	O
the	the	O	O	O	O
inciting	inciting	O	O	O	O
agent	agent	O	O	O	O
is	is	O	O	O	O
not	not	O	O	O	O
without	without	O	O	O	O
the	the	O	O	O	O
attendant	attendant	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
precipitating	precipitating	O	O	O	O
acute	acute	O	O	O	O
rejection	rejection	O	O	O	O
and	and	O	O	O	O
graft	graft	O	O	O	O
loss	loss	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
last	last	O	O	O	O
decade	decade	O	O	O	O
has	has	O	O	O	O
seen	seen	O	O	O	O
the	the	O	O	O	O
emergence	emergence	O	O	O	O
of	of	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
potent	potent	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
agent	agent	O	O	O	O
with	with	O	O	O	O
mechanisms	mechanisms	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
virtually	virtually	O	O	O	O
identical	identical	O	O	O	O
to	to	O	O	O	O
those	those	O	O	O	O
of	of	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

As	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
,	,	O	O	O	O
switching	switching	O	O	O	O
to	to	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
viable	viable	O	O	O	O
therapeutic	therapeutic	O	O	O	O
option	option	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
setting	setting	O	O	O	O
of	of	O	O	O	O
cyclosporine-induced	cyclosporine-induced	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

With	with	O	O	O	O
the	the	O	O	O	O
more	more	O	O	O	O
widespread	widespread	O	O	O	O
application	application	O	O	O	O
of	of	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
organ	organ	O	O	O	O
transplantation	transplantation	O	O	O	O
,	,	O	O	O	O
tacrolimus-associated	tacrolimus-associated	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
has	has	O	O	O	O
also	also	O	O	O	O
been	been	O	O	O	O
recognized	recognized	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
literature	literature	O	O	O	O
regarding	regarding	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
exposed	exposed	O	O	O	O
sequentially	sequentially	O	O	O	O
to	to	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
limited	limited	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
living	living	O	O	O	O
donor	donor	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipient	recipient	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
cyclosporine-induced	cyclosporine-induced	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
that	that	O	O	O	O
responded	responded	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
withdrawal	withdrawal	O	O	O	O
of	of	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
conjunction	conjunction	O	O	O	O
with	with	O	O	O	O
plasmapheresis	plasmapheresis	O	O	O	O
and	and	O	O	O	O
fresh	fresh	O	O	O	O
frozen	frozen	O	O	O	O
plasma	plasma	O	O	O	O
replacement	replacement	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Introduction	introduction	O	O	O	O
of	of	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
an	an	O	O	O	O
alternative	alternative	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
agent	agent	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
subsequent	subsequent	O	O	O	O
loss	loss	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
renal	renal	O	O	O	O
allograft	allograft	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
switched	switched	O	O	O	O
from	from	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
vice	vice	O	O	O	O
versa	versa	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
closely	closely	O	O	O	O
monitored	monitored	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
signs	signs	O	DISEASE	OTHERS	I
and	and	O	DISEASE	OTHERS	I
symptoms	symptoms	O	DISEASE	OTHERS	I
of	of	O	O	O	O
recurrent	recurrent	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

